

# Parent Initiated Prednisolone in Asthma (PIPA)

<b>Submission date</b> 22/02/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 05/05/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 03/03/2010	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Peter Vuillermin

**Contact details**  
Geelong Hospital  
P.O. Box 281  
Ryrie St  
Geelong  
Australia  
3220  
+61 (0)3 5260 3044  
peter.vuillermin@telstra.com

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

**Secondary identifying numbers**  
NA

## Study information

**Scientific Title**

Parent Initiated Prednisolone in Asthma (PIPA): a randomised, placebo-controlled, crossover trial

**Acronym**

PIPA

**Study objectives**

Parent initiated prednisolone, when compared with placebo, in the setting of an episode of acute asthma is associated with a reduction in the mean asthma daytime symptom score

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised placebo controlled crossover group trial

**Primary study design**

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

Not specified

**Study type(s)**

Treatment

**Participant information sheet****Health condition(s) or problem(s) studied**

Asthma

**Interventions**

A short course of parent initiated oral prednisolone or placebo, administered as a single daily dose of 1 mg per kg in 10 mg brackets to a maximum of 50 mg daily.

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Prednisolone

**Primary outcome measure**

The mean 7-day asthma daytime symptom score.

### **Secondary outcome measures**

1. Nocturnal symptom scores
2. Asthma free days
3. Days of school missed
4. Days of parental work missed
5. Unscheduled medical review due to acute asthma
6. Use of the participant's regular reliever medication
7. Prescription of a corticosteroid by the participant's physician for an asthma exacerbation
8. Adverse effects (including growth and behavioural changes)

### **Overall study start date**

28/02/2005

### **Completion date**

28/02/2007

## **Eligibility**

### **Key inclusion criteria**

1. Age: 5 to 11 years old
2. Definition of asthma: a history of recurrent episodes of bronchodilator responsive wheeze. This will be determined in each case by the principal investigator.
3. Asthma severity: four or more acute asthma exacerbations in the preceding 12 months. Asthma exacerbations will be defined as a subjective worsening of lung function that failed to respond to appropriate doses of 'reliever' medication within a 6 hour period.

### **Participant type(s)**

Patient

### **Age group**

Child

### **Lower age limit**

5 Years

### **Upper age limit**

11 Years

### **Sex**

Both

### **Target number of participants**

308

### **Key exclusion criteria**

1. Receiving systemic steroids daily or on alternate days
2. Chronic disease, other than asthma, that affects pulmonary function
3. Insulin dependent diabetes mellitus

**Date of first enrolment**

28/02/2005

**Date of final enrolment**

28/02/2007

## **Locations**

**Countries of recruitment**

Australia

**Study participating centre****Geelong Hospital**

Geelong

Australia

3220

## **Sponsor information**

**Organisation**

Murdoch Children's Research Institute (Australia)

**Sponsor details**

10th Floor

Royal Children's Hospital

Flemington Rd

Parkville

Australia

3052

+61 (0)3 8341 6111

julia.malone@mcri.edu.au

**Sponsor type**

Research organisation

**ROR**

<https://ror.org/048fyec77>

## **Funder(s)**

**Funder type**

Charity

**Funder Name**

The Jack Brockhoff Foundation (Australia)

**Funder Name**

The Murdoch Children's Research Institute (Australia)

**Funder Name**

The Percy Baxter Foundation (Australia)

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/03/2010		Yes	No